Executive Summary On July 28, 2014, the Department of Health and Human Services Office of Inspector General (“OIG”) released Advisory Opinion No. 14-05 (“AO 14-05”), addressing one of OIG’s favorite foci, federal health care program “carve out” arrangements. AO 14-05 was issued in response to a pharmaceutical manufacturer’s (“Company”) request for review of its direct-to-patient…Read More
OIG Releases Advisory Opinion on Pharmaceutical Direct-to-Patient Sales Program
Posted on August 7, 2014 in Health Law News
Published by: Hall Render